-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In response to Pfizer's failure to enter the medical insurance catalog through medical insurance negotiations, Huang Xinyu, deputy director of the Department of Pharmaceutical Service Management of the National Medical Insurance Administration, said in Beijing on the 11th that although Paxlovid failed to negotiate successfully this time, according to the current new crown drug reimbursement policy, Paxlovid can still be temporarily reimbursed until March 31
, 2023.
In addition, there are more than 600 kinds of new crown symptomatic treatment drugs in the current version of the medical insurance catalog, and the types of medical insurance drugs are still relatively rich
.
, 2023.
In addition, there are more than 600 kinds of new crown symptomatic treatment drugs in the current version of the medical insurance catalog, and the types of medical insurance drugs are still relatively rich
.
On the 11th, the joint prevention and control mechanism of the State Council held a press conference
on the situation of epidemic prevention and control in key institutions and key places.
on the situation of epidemic prevention and control in key institutions and key places.
Huang Xinyu said that the National Health Insurance Administration attaches great importance to the issue of
drug protection for new crown treatment.
At the beginning of the epidemic in 2020, the National Health Insurance Administration promptly issued the "two guarantees" new crown cost guarantee policy, temporarily including the non-listed drugs in the new crown diagnosis and treatment plan into the scope of medical insurance payment
.
Follow-up will be followed up in time with the update of the diagnosis and treatment plan
.
drug protection for new crown treatment.
At the beginning of the epidemic in 2020, the National Health Insurance Administration promptly issued the "two guarantees" new crown cost guarantee policy, temporarily including the non-listed drugs in the new crown diagnosis and treatment plan into the scope of medical insurance payment
.
Follow-up will be followed up in time with the update of the diagnosis and treatment plan
.
Huang Xinyu said that in the just-concluded 2022 medical insurance catalog negotiations, a total of 3 new crown treatment drugs participated in the negotiations, among which azvudine tablets and lung cleansing detoxification granules were successfully
negotiated.
Although Paxlovid was unable to negotiate successfully this time, according to the current new crown drug reimbursement policy, Paxlovid can still be temporarily reimbursed until March 31
, 2023.
negotiated.
Although Paxlovid was unable to negotiate successfully this time, according to the current new crown drug reimbursement policy, Paxlovid can still be temporarily reimbursed until March 31
, 2023.
He said that with the changes in the epidemic situation, the Notice on Optimizing the Medical Security for Treatment Costs of Patients with Novel Coronavirus Infection after the Implementation of "Class B and B Tubes" jointly issued by the National Medical Insurance Administration and relevant departments continued the temporary reimbursement policy for off-list new crown treatment drugs, and paid in advance until March 31, 2023, during which the reimbursement of patients' medication was not affected
.
.
"In addition, there are more than 600 kinds of new crown symptomatic treatment drugs in the current version of the medical insurance catalog, and it should be said that the types of medical insurance drugs are still relatively rich
.
" Huang Xinyu said
.
.
" Huang Xinyu said
.
According to media reports, there are also some other new crown treatment drugs that have been launched
recently.
Huang Xinyu said that he believes that with the increase of new drugs on the market, the level of protection and ability of new crown treatment drugs will steadily improve
.
In the next step, we will continue to strengthen the price monitoring and management of new crown treatment drugs, reduce the economic burden of patients, and make every effort to ensure the relevant costs
.
recently.
Huang Xinyu said that he believes that with the increase of new drugs on the market, the level of protection and ability of new crown treatment drugs will steadily improve
.
In the next step, we will continue to strengthen the price monitoring and management of new crown treatment drugs, reduce the economic burden of patients, and make every effort to ensure the relevant costs
.
